MX2022015799A - Composicion y metodo para el tratamiento del dolor cronico. - Google Patents

Composicion y metodo para el tratamiento del dolor cronico.

Info

Publication number
MX2022015799A
MX2022015799A MX2022015799A MX2022015799A MX2022015799A MX 2022015799 A MX2022015799 A MX 2022015799A MX 2022015799 A MX2022015799 A MX 2022015799A MX 2022015799 A MX2022015799 A MX 2022015799A MX 2022015799 A MX2022015799 A MX 2022015799A
Authority
MX
Mexico
Prior art keywords
chronic pain
composition
treating chronic
relates
treating
Prior art date
Application number
MX2022015799A
Other languages
English (en)
Inventor
Richard Hopkins
Meghan Gail Thomas
Oludare Odumosu
Original Assignee
Zelira Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901947A external-priority patent/AU2020901947A0/en
Application filed by Zelira Therapeutics Operations Pty Ltd filed Critical Zelira Therapeutics Operations Pty Ltd
Publication of MX2022015799A publication Critical patent/MX2022015799A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K36/3482—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La invención se refiere a composiciones farmacéuticas que comprenden ?9 -tetrahidrocannabinol (THC), cannabidiol (CBD) y cannabigerol (CBG) y un componente terpeno, y su uso en el tratamiento del dolor crónico. La invención también se refiere a métodos para tratar el dolor crónico, especialmente el dolor crónico en atletas.
MX2022015799A 2020-06-12 2021-06-11 Composicion y metodo para el tratamiento del dolor cronico. MX2022015799A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020901947A AU2020901947A0 (en) 2020-06-12 Composition and method for treating chronic pain
PCT/AU2021/050602 WO2021248207A1 (en) 2020-06-12 2021-06-11 Composition and method for treating chronic pain

Publications (1)

Publication Number Publication Date
MX2022015799A true MX2022015799A (es) 2023-04-11

Family

ID=78523907

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015799A MX2022015799A (es) 2020-06-12 2021-06-11 Composicion y metodo para el tratamiento del dolor cronico.

Country Status (14)

Country Link
US (1) US20230218566A1 (es)
EP (1) EP4164628A1 (es)
JP (1) JP2023529476A (es)
KR (1) KR20230069080A (es)
CN (1) CN115843248A (es)
AU (1) AU2021215262B2 (es)
BR (1) BR112022025302A2 (es)
CA (1) CA3186718A1 (es)
CL (1) CL2022003507A1 (es)
CO (1) CO2023000130A2 (es)
IL (1) IL299008A (es)
MX (1) MX2022015799A (es)
PE (1) PE20230837A1 (es)
WO (1) WO2021248207A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220387256A1 (en) * 2021-06-03 2022-12-08 Kent Byron Vial With Metered Dispenser

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11304925B1 (en) * 2016-08-03 2022-04-19 Zelda Therapeutics Operations Pty Ltd Cannabis composition
WO2019036243A1 (en) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations
WO2019056128A1 (en) * 2017-09-25 2019-03-28 Canopy Health Innovations COMPOSITIONS COMPRISING CANNABIDIOL, TETRAHYDROCANNABINOL, TERPENES AND FLAVONOIDS AND THEIR USE IN THE TREATMENT OF INSOMNIA
EP3703672A4 (en) * 2017-10-30 2021-12-01 Endocanna Health, Inc. CANNABINOID FORMULATIONS
BR112020017023A2 (pt) * 2018-02-23 2021-03-02 Nicola Michael Spirtos terapêutica à base de cannabis e método de uso
CN112969452A (zh) * 2018-04-09 2021-06-15 艾乐文特科学公司 用于治疗动物疼痛的大麻提取物
AU2018100928A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for opioid sparing
AU2018100924A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for treating pain
EP3876918A4 (en) * 2018-11-09 2022-08-10 Cronos Group Inc. LIQUID COMPOSITION FOR AN ELECTRONIC VAPOR DEVICE
CA3027876A1 (en) * 2018-12-18 2020-06-18 Tetra Bio-Pharma Cannabis compositions and methods

Also Published As

Publication number Publication date
CL2022003507A1 (es) 2023-06-09
PE20230837A1 (es) 2023-05-19
JP2023529476A (ja) 2023-07-10
KR20230069080A (ko) 2023-05-18
US20230218566A1 (en) 2023-07-13
IL299008A (en) 2023-02-01
CN115843248A (zh) 2023-03-24
CO2023000130A2 (es) 2023-05-19
CA3186718A1 (en) 2021-12-16
AU2021215262A1 (en) 2021-11-04
AU2021215262B2 (en) 2023-12-14
BR112022025302A2 (pt) 2023-02-28
EP4164628A1 (en) 2023-04-19
WO2021248207A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
MX2021000020A (es) Composicion y metodo para tratar el dolor.
MX2019015315A (es) Composiciones y tratamientos para el trastorno del sueño.
Farid et al. Oral intake of purple passion fruit peel extract reduces pain and stiffness and improves physical function in adult patients with knee osteoarthritis
NZ729290A (en) Composition containing a mixture of plant extracts or a mixture of molecules contained in said plants, and use for controlling carbohydrate and/or lipid metabolism
MX2021006270A (es) Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa.
MX2019001286A (es) Composicion de cannabis.
BRPI0511322A (pt) composições adequadas para o tratamento de sinais cutáneos provenientes do envelhecimento, tablete e formulação de tablete
ECSP055706A (es) Composición que comprende extractos de panax ginseng y paullinia cupana
BR112013000027A2 (pt) tratamento de distúrbios cognitivos
FR2949044B1 (fr) Composition comprenant une fraction d'insaponifiable
NO20061236L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og paratyroidhoziiton
MX2023006561A (es) Formulaciones farmaceuticas transdermicas que comprenden cbd o thc para el tratamiento del cancer.
MX2021000023A (es) Composicion y metodo para el ahorro de opioides.
MX2019009952A (es) Formulaciones de evolocumab de baja viscosidad y alta concentracion y metodos de elaboracion de las mismas.
ATE361746T1 (de) Botanischer extrakt mit antikrebs-aktivität enthaltend isoliquiritigenin
KR20070008451A (ko) 골관절염의 치료 방법
MX2022015799A (es) Composicion y metodo para el tratamiento del dolor cronico.
KR20170082576A (ko) 락토바실러스 람노서스를 보유한 기능식품 보충제
TW200724150A (en) Plant extracts for treating skin disorders and enhancing healing of wounds for diabetics patients
EP2575456A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ECCHYMOSIS
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
PH12017502145A1 (en) Composition and uses thereof
MX2022007720A (es) Extractos enriquecidos con compuestos polifenolicos y metodos relacionados.
BRPI0913665B8 (pt) composição para tratamento de pressão intraocular aumentada em um paciente, compreendendo extratos de vaccinum myrtillus e de casca de pinheiro
GB2415905A (en) Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising prenyl flavonoids